Dennis Slamon and colleagues helped connect HER2 amplification with the behavior of a subset of breast cancers. Their work contributed to the evidence chain that led to trastuzumab: a measurable alteration became an experimental target, then a treatment tested in patients. The story also shows why breast cancer biomarkers need both biological and clinical validation.
Dennis Slamon and colleagues played a central role in that chain, working within a much larger network of academic, government, and industry researchers. NCI: HER2 Genetic Link to Breast Cancer
The 1987 HER2 amplification study
In a landmark 1987 Science paper, Slamon and colleagues studied HER-2/neu in 189 primary breast cancers. In that historical cohort, amplification of the gene was associated with shorter time to relapse and worse overall survival. The result suggested that HER2 was not merely present in cancer cells—it might help define a biologically aggressive subset of disease. Slamon et al., Science (1987)
The exact percentages reported in that paper should not be treated as current population prevalence estimates. Diagnostic methods and clinical classification have changed. The durable point is the relationship the study established between a measurable genomic alteration and disease behavior.
Testing whether HER2 could drive tumor growth
A prognostic association does not prove that a protein is functionally driving the cancer. Researchers therefore needed experiments showing that altering HER2 activity could change tumor-cell behavior.
NCI’s historical account describes parallel work showing that HER2 could drive uncontrolled growth and that antibodies directed against HER2 could suppress growth in preclinical models. Those experiments turned a correlation into a therapeutic hypothesis: if the cancer depends on HER2 signaling, blocking HER2 may slow the disease.
How experimental antibodies led to trastuzumab
Genentech researchers developed a humanized HER2-directed monoclonal antibody that became trastuzumab. Collaboration among academic investigators, industry scientists, clinical researchers, and patients then tested whether the mechanism translated into clinical benefit.
FDA approved trastuzumab for HER2-positive metastatic breast cancer in 1998. Later randomized trials demonstrated benefit in early-stage HER2-positive disease, moving HER2-directed therapy into the adjuvant setting.
The 2005 HERA trial in early breast cancer
In the HERA trial, one year of trastuzumab after chemotherapy significantly improved disease-free survival compared with observation in HER2-positive early breast cancer. The study also highlighted an important part of translational research: a treatment can produce meaningful benefit and still require careful attention to toxicity, including cardiac risk. HERA Trial, New England Journal of Medicine (2005)
How HER2 research shaped targeted therapy
The lasting lesson is the sequence of reasoning. First identify a reproducible biological alteration. Then ask whether it changes cancer behavior. Then interfere with the mechanism. Finally, test the intervention in a biomarker-defined patient population.
That framework now extends far beyond trastuzumab. Newer HER2-directed antibodies, kinase inhibitors, and antibody–drug conjugates all build on the idea that target biology can guide treatment—but their mechanisms and effective patient populations are not identical.
Why the discovery required many teams
Scientific history often becomes attached to a few recognizable names. The HER2 story is better understood as a network: molecular biologists identified the receptor family, clinical researchers connected HER2 amplification with breast cancer behavior, antibody engineers developed therapeutic molecules, and trial teams established whether those molecules helped patients.
Slamon’s contribution helped connect molecular observation with a clinically testable target. The wider achievement depended on many teams building and testing that connection. The landmark breast cancer papers behind this story make the transition from association to clinical benefit easier to examine.
This article is intended for scientific education and does not provide individualized medical advice, diagnosis, or treatment recommendations.
Sources and further reading
- NCI — HER2’s Genetic Link to Breast Cancer
- Slamon et al. — Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene
- Piccart-Gebhart et al. — Trastuzumab After Adjuvant Chemotherapy in HER2-Positive Breast Cancer
- NCI — Milestones in Cancer Research and Discovery
